Compare Gilead Sciences, Inc. (GILD) vs Indonesia Energy Corporation Limited (INDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Indonesia Energy Corporation Limited — how do they compare? Gilead Sciences, Inc. trades at $132.95 (market cap $163.51B), while Indonesia Energy Corporation Limited trades at $2.94 (market cap $44.01M). The key difference: Gilead Sciences, Inc. is far larger — about 3715.3× Indonesia Energy Corporation Limited's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Indonesia Energy Corporation Limited pays none. Which is the better fit depends on your goals.
| GILD | INDO | |
|---|---|---|
Market Cap | $163.51B | $44.01M |
Sector | Health | Energy |
52-Week High | $155.80 | $6.74 |
52-Week Low | $108.22 | $2.49 |
Enterprise Value | $178.05B | $39.38M |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Indonesia Energy Corporation (INDO) trades at $2.95, showing modest daily gains. The technical picture is neutral, while fundamental metrics reveal significant challenges with negative profitability margins and a high P/S ratio of 20.84. Recent news is operationally positive, highlighting the commencement of drilling at the Kruh Block. Analyst sentiment is unanimously bullish with a 100% buy rating from three covering firms, indicating strong forward expectations despite current financial losses.
The investment case hinges on successful execution of new well operations to drive future revenue and reverse deep losses. Key risks include sustained negative cash flow from operations (-$5M in 2025), high valuation relative to sales, and execution risks in exploration. The unanimous analyst buy consensus suggests the market is pricing in a successful operational turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →
